In June, following a placebo-controlled trial, the FDA approved pembrolizumab with chemotherapy to treat patients with primary advanced or recurrent endometrial carcinoma.
Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
The drug is approved as a diagnostic tool to help identify cancerous lesions during surgery, which is normally difficult to detect. The drug is administered intravenously prior to surgery.